vimarsana.com
Home
Live Updates
Atrial Fibrillation Study with Abelacimab Stopped Early by t
Atrial Fibrillation Study with Abelacimab Stopped Early by t
Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC
Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-toHead Study Comparing a Factor XI Inhibitor to a DOAC
Related Keywords
United States ,
American ,
Lewis Dexter ,
Thromb Haemost ,
Marcs Sabatine ,
Dan Bloomfield ,
Coll Cardiol ,
Harvard Medical School ,
Data Monitoring Committee ,
Blackstone Life Sciences ,
Study Group ,
National Blood Clot Alliance ,
Anthos Therapeutics Inc ,
Anthos Therapeutics ,
Distinguished Chair ,
Cardiovascular Medicine ,
Myocardial Infarction ,
New England Journal ,
Chief Medical Officer ,
Disease Control ,
Leslie Lake ,
National Blood Clot ,
Englj Med July ,
Atrial Fibrillation ,
American Heart Journal ,